NCT00516100View on ClinicalTrials.gov

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

August 31, 2012

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

bortezomib

MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.

Trial Locations (4)

90048

Cedars-Sinai Outpatient Cancer Center, Los Angeles

92262

Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs

94115

California Pacific Medical Center, San Francisco

07207

Trinitas Comprehensive Cancer Center, Elizabeth

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Aptium Oncology Research Network

NETWORK